lebrikizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5759 953400-68-5

Description:

MoleculeDescription

Molfile

Synonyms:

  • lebrikizumab
  • MILR1444A
  • PRO301444
  • ebglyss
Lebrikizumab is an immunoglobulin (IgG4) monoclonal antibody that binds with high affinity to interleukin (IL)-13 and selectively inhibits IL-13 signalling through the IL-4 receptor alpha (IL-4Ralpha)/ IL-13 receptor alpha 1 (IL-13Ralpha1) heterodimer, thereby inhibiting the downstream effects of IL-13. Inhibition of IL-13 signalling is expected to be of benefit in diseases in which IL-13 is a key contributor to the disease pathogenesis. Lebrikizumab does not prevent the binding of IL-13 to the IL-13 receptor alpha 2 (IL-13Ralpha2 or decoy receptor), which allows the internalisation of IL-13 into the cell.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
8.90 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Nov. 16, 2023 EMA ALMIRALL, S.A.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis atopic 91.64 66.69 21 371 23451 90604604
Pruritus 80.69 66.69 41 351 541484 90086571
Dry skin 76.54 66.69 24 368 88049 90540006

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis atopic 87.79 57.65 20 387 25521 110563371
Pruritus 75.09 57.65 38 369 581522 110007370
Eczema 71.54 57.65 21 386 72272 110516620
Dry skin 67.35 57.65 22 385 107631 110481261

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D11AH10 DERMATOLOGICALS
OTHER DERMATOLOGICAL PREPARATIONS
OTHER DERMATOLOGICAL PREPARATIONS
Agents for dermatitis, excluding corticosteroids
FDA EPC N0000193985 Interleukin-13 Antagonist
FDA MoA N0000193986 Interleukin-13 Antagonists
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:50177 dermatologic drug
CHEBI has role CHEBI:65023 anti-asthmatic agent
CHEBI has role CHEBI:233423 antifibrotic agent

Related Drugs by ATC class:

D11AH Agents for dermatitis, excluding corticosteroids 11 drugs
abrocitinibalitretinoincrisaborolecromoglicic aciddelgocitinibdupilumabnemolizumabpimecrolimusruxolitinibtacrolimustralokinumab

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Moderate to severe atopic dermatitis indication 24079001 DOID:3310




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interleukin-13 Cytokine INHIBITOR Kd 9.73 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
CHEMBL1743035 ChEMBL_ID
C561806 MESH_SUPPLEMENTAL_RECORD_UI
7684 IUPHAR_LIGAND_ID
DB11914 DRUGBANK_ID
4043406 VANDF
C2981360 UMLSCUI
CHEBI:750113 CHEBI
9165 INN_ID
43079 MMSL
d10214 MMSL
U9JLP7V031 UNII
2693758 RXNORM
1351535000 SNOMEDCT_US
D09633 KEGG_DRUG

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
EBGLYSS HUMAN PRESCRIPTION DRUG LABEL 1 0002-7772 INJECTION, SOLUTION 250 mg SUBCUTANEOUS BLA 30 sections
EBGLYSS HUMAN PRESCRIPTION DRUG LABEL 1 0002-7797 INJECTION, SOLUTION 250 mg SUBCUTANEOUS BLA 30 sections